Pacira BioSciences - PCRX Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $49.50
Forecasted Upside: 84.01%
Number of Analysts: 10
Breakdown:
0 Sell Ratings
0 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$26.90 As of 04/23/2024 01:28 PM ET

▲ +0.8 (3.07%)

1 month | 3 months | 12 months

Get New Pacira BioSciences Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for PCRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PCRX

^$49.50

▲ +84.01% Upside Potential

This price target is based on 10 analysts offering 12 month price targets for Pacira BioSciences in the last 3 months. The average price target is $49.50, with a high forecast of $57.00 and a low forecast of $42.00. The average price target represents a 84.01% upside from the last price of $26.90.

Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in Pacira BioSciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/31/2022

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/29/2023

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/29/2023

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/28/2023

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/26/2023

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/24/2024

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/24/2024

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/23/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/9/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$45.00	Low
3/7/2024	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$80.00 ➝ $45.00	Low
3/4/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$57.00	Low
3/1/2024	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$53.00 ➝ $45.00	Low
3/1/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$45.00	Low
2/8/2024	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$57.00	Low
1/5/2024	Wedbush	Reiterated Rating	Outperform	$57.00	Low
12/20/2023	Raymond James	Initiated Coverage	Outperform	$42.00	Low
11/6/2023	HC Wainwright	Lower Target	Buy ➝ Buy	$63.00 ➝ $57.00	Low
11/3/2023	Piper Sandler	Lower Target	Overweight ➝ Overweight	$50.00 ➝ $42.00	Low
11/3/2023	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$67.00 ➝ $58.00	Low
11/3/2023	Needham & Company LLC	Lower Target	Buy ➝ Buy	$52.00 ➝ $45.00	N/A
10/23/2023	Barclays	Lower Target	Overweight ➝ Overweight	$60.00 ➝ $57.00	Low
10/3/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$68.00	Low
8/3/2023	Piper Sandler	Lower Target	Overweight ➝ Overweight	$60.00 ➝ $50.00	Low
8/3/2023	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$70.00 ➝ $68.00	Low
8/3/2023	Needham & Company LLC	Lower Target	Buy ➝ Buy	$60.00 ➝ $52.00	Low
8/3/2023	Truist Financial	Lower Target	Buy ➝ Buy	$60.00 ➝ $55.00	N/A
8/3/2023	TD Cowen	Upgrade	Market Perform ➝ Outperform	$50.00	Low
8/3/2023	HC Wainwright	Lower Target	Buy ➝ Buy	$68.00 ➝ $63.00	Low
7/13/2023	HC Wainwright	Lower Target		$71.00 ➝ $68.00	Low
4/25/2023	Piper Sandler	Lower Target		$63.00 ➝ $62.00	Low
4/20/2023	Needham & Company LLC	Reiterated Rating	Buy	$60.00	Low
3/3/2023	Barclays	Lower Target		$90.00 ➝ $80.00	Low
3/1/2023	Royal Bank of Canada	Lower Target	Outperform	$80.00 ➝ $76.00	Low
3/1/2023	HC Wainwright	Boost Target	Buy	$69.00 ➝ $71.00	Low
2/28/2023	Needham & Company LLC	Lower Target	Buy	$63.00 ➝ $60.00	Low
2/10/2023	HC Wainwright	Lower Target	Buy	$76.00 ➝ $69.00	Low
1/31/2023	Wedbush	Reiterated Rating	Outperform	$60.00	Low
1/18/2023	Truist Financial	Lower Target		$68.00 ➝ $63.00	Low
1/6/2023	BMO Capital Markets	Lower Target	Market Perform	$60.00 ➝ $52.00	Low
1/6/2023	Needham & Company LLC	Lower Target	Buy	$66.00 ➝ $63.00	Low
12/21/2022	Wedbush	Reiterated Rating	Buy	$88.00	Low
12/14/2022	Cowen	Lower Target		$54.00 ➝ $50.00	Low
12/14/2022	Cowen	Lower Target		$54.00 ➝ $50.00	Low
11/7/2022	BMO Capital Markets	Lower Target	Market Perform	$66.00 ➝ $60.00	Low
11/4/2022	HC Wainwright	Lower Target	Buy	$83.00 ➝ $76.00	N/A
11/3/2022	Needham & Company LLC	Lower Target	Buy	$76.00 ➝ $74.00	Low
10/21/2022	Jefferies Financial Group	Initiated Coverage	Buy	$66.00	Low
9/21/2022	Wedbush	Reiterated Rating	Outperform	$94.00	Low
7/21/2022	Piper Sandler	Lower Target	Overweight	$84.00 ➝ $80.00	Low
6/15/2022	Needham & Company LLC	Lower Target	Buy	$84.00 ➝ $76.00	High
3/1/2022	Northland Securities	Boost Target		$61.00 ➝ $67.00	High
2/26/2022	Wedbush	Reiterated Rating	Buy	$97.00 ➝ $94.00	Medium
2/25/2022	HC Wainwright	Boost Target	Buy	$86.00 ➝ $90.00	High
2/16/2022	Wedbush	Reiterated Rating	Buy	$97.00	Low
1/19/2022	Barclays	Boost Target	Overweight	$92.00 ➝ $96.00	Low
1/7/2022	Wedbush	Reiterated Rating	Buy	$97.00	High
1/4/2022	Northland Securities	Boost Target		$57.00 ➝ $61.00	Medium
1/3/2022	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$83.00	Medium
11/5/2021	Barclays	Boost Target	Overweight	$91.00 ➝ $92.00	High
11/4/2021	HC Wainwright	Boost Target	Buy	$80.00 ➝ $86.00	Low
10/18/2021	Needham & Company LLC	Boost Target	Buy	$80.00 ➝ $84.00	Low
10/12/2021	HC Wainwright	Lower Target	Buy	$84.00 ➝ $80.00	Medium
10/12/2021	BMO Capital Markets	Lower Target	Market Perform	$66.00 ➝ $60.00	Medium
10/5/2021	Northland Securities	Lower Target	Market Perform	$66.00 ➝ $57.00	High
10/1/2021	Barclays	Lower Target	Overweight	$95.00 ➝ $91.00	High
9/22/2021	Wedbush	Reiterated Rating	Buy	$93.00	Low
8/4/2021	HC Wainwright	Lower Target	Buy	$86.00 ➝ $84.00	Medium
7/26/2021	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$70.00 ➝ $75.00	Low
7/14/2021	HC Wainwright	Reiterated Rating	Buy	$86.00	Low
5/10/2021	BMO Capital Markets	Lower Target	Market Perform	$72.00 ➝ $70.00	Medium
5/5/2021	Northland Securities	Lower Target	Market Perform	$75.00 ➝ $66.00	Low
4/9/2021	Berenberg Bank	Initiated Coverage	Buy	$93.00	Low
3/1/2021	HC Wainwright	Boost Target	Buy	$70.00 ➝ $86.00	Low
2/26/2021	Barclays	Boost Target	Overweight	$79.00 ➝ $94.00	Medium
2/11/2021	Northland Securities	Downgrade	Outperform ➝ Market Perform	$72.00 ➝ $75.00	Low
1/25/2021	Northland Securities	Boost Target	Outperform	$67.00 ➝ $72.00	Medium
1/21/2021	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$63.00 ➝ $75.00	High
1/20/2021	Piper Sandler	Boost Target	Overweight	$65.00 ➝ $90.00	Low
1/8/2021	Needham & Company LLC	Boost Target	Buy	$67.00 ➝ $76.00	High
1/6/2021	Royal Bank of Canada	Boost Target	Outperform	$65.00 ➝ $70.00	N/A
12/14/2020	Barclays	Boost Target	Overweight	$73.00 ➝ $79.00	Low
12/9/2020	Needham & Company LLC	Lower Target	Buy	$68.00 ➝ $67.00	High
11/2/2020	Wedbush	Lower Target	Outperform	$85.00 ➝ $83.00	Low
10/7/2020	Wedbush	Reiterated Rating	Buy	$85.00	Medium
9/30/2020	Jefferies Financial Group	Boost Target		$69.00 ➝ $75.00	Low
9/21/2020	Northland Securities	Upgrade	Market Perform ➝ Outperform	$58.00 ➝ $67.00	Medium
9/9/2020	Needham & Company LLC	Boost Target	Buy	$64.00 ➝ $68.00	High
8/17/2020	Wedbush	Reiterated Rating	Buy	$85.00	Medium
8/14/2020	Truist Financial	Boost Target		$54.00 ➝ $65.00	Low
8/10/2020	HC Wainwright	Boost Target	Buy	$68.00 ➝ $70.00	High
7/20/2020	Wedbush	Reiterated Rating	Buy	$85.00	Low
7/13/2020	HC Wainwright	Reiterated Rating	Buy	$63.00 ➝ $68.00	High
7/10/2020	Jefferies Financial Group	Boost Target	Buy	$53.00 ➝ $69.00	Low
7/6/2020	Needham & Company LLC	Boost Target	Buy	$52.00 ➝ $64.00	Medium
7/6/2020	Piper Sandler	Boost Target	Positive ➝ Overweight	$49.00 ➝ $65.00	Medium
7/2/2020	Wedbush	Reiterated Rating	Buy	$85.00	N/A
7/1/2020	Royal Bank of Canada	Boost Target	Outperform	$56.00 ➝ $62.00	High
6/30/2020	SVB Leerink	Boost Target	Outperform	$45.00 ➝ $58.00	Medium
6/30/2020	Northland Securities	Boost Target	Market Perform	$50.00 ➝ $54.00	Low
5/27/2020	Northland Securities	Downgrade	Outperform ➝ Market Perform		Low
5/26/2020	Guggenheim	Initiated Coverage	Neutral		Low
5/13/2020	Royal Bank of Canada	Reiterated Rating	Buy	$56.00	High
5/12/2020	Wedbush	Reiterated Rating	Buy	$85.00	High
5/8/2020	SVB Leerink	Boost Target	Buy	$44.00 ➝ $45.00	Medium
5/7/2020	Stifel Nicolaus	Lower Target	Hold	$49.00 ➝ $48.00	Low
4/30/2020	Needham & Company LLC	Lower Target	Buy	$56.00 ➝ $52.00	High
4/27/2020	Wedbush	Reiterated Rating	Buy	$85.00	Medium
4/17/2020	Northland Securities	Reiterated Rating	Buy	$50.00	High
4/7/2020	Northland Securities	Initiated Coverage	Outperform	$50.00	High
3/23/2020	Piper Sandler	Lower Target		$60.00 ➝ $49.00	High
3/23/2020	Royal Bank of Canada	Lower Target	Outperform	$65.00 ➝ $56.00	High
3/20/2020	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$46.00 ➝ $44.00	High
2/24/2020	HC Wainwright	Boost Target	Buy	$60.00 ➝ $63.00	Medium
2/20/2020	Wedbush	Reiterated Rating	Buy	$85.00	N/A
2/20/2020	Stifel Nicolaus	Reiterated Rating	Hold	$49.00	High
2/20/2020	Piper Sandler	Boost Target	Buy	$54.00 ➝ $60.00	Low
1/23/2020	SunTrust Banks	Initiated Coverage	Buy	$60.00	Low
1/7/2020	Wedbush	Reiterated Rating	Buy	$85.00	Low
12/18/2019	Royal Bank of Canada	Reiterated Rating	Buy		Low
12/17/2019	Wedbush	Reiterated Rating	Buy	$85.00	Medium
11/8/2019	Barclays	Boost Target	Overweight	$52.00 ➝ $55.00	Medium
11/7/2019	Needham & Company LLC	Reiterated Rating	Buy	$56.00	High
11/7/2019	Cowen	Reiterated Rating	Hold	$41.00	High
11/6/2019	BTIG Research	Initiated Coverage	Buy	$56.00 ➝ $56.00	Medium
10/8/2019	Jefferies Financial Group	Set Target	Buy	$60.00	Low
8/9/2019	Stifel Nicolaus	Set Target	Hold	$42.00	Low
8/9/2019	BMO Capital Markets	Lower Target	Market Perform	$46.00 ➝ $43.00	Low
6/28/2019	Wedbush	Set Target	Buy	$85.00	Medium
6/12/2019	Wedbush	Reiterated Rating	Outperform	$85.00	Low
6/11/2019	Barclays	Initiated Coverage	Overweight ➝ Overweight	$52.00	Low
5/6/2019	Mizuho	Upgrade	Underperform ➝ Neutral	$29.00 ➝ $38.00	Low
5/3/2019	BMO Capital Markets	Set Target	Hold	$46.00	Low
5/2/2019	Stifel Nicolaus	Upgrade	Sell ➝ Hold	$45.00	Low

(Data available from 4/23/2019 forward)

News Sentiment Rating

0.62 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

4 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/26/2023

7 very positive mentions
4 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

10/26/2023

4 very positive mentions
6 positive mentions
4 negative mentions
0 very negative mentions

Mentions as of

11/25/2023

1 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/25/2023

6 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/24/2024

19 very positive mentions
6 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/23/2024

15 very positive mentions
16 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

3/24/2024

7 very positive mentions
5 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

4/23/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Today's Range

Now: $26.90

$26.19

$27.00

50 Day Range

MA: $28.96

$26.10

$31.41

52 Week Range

Now: $26.90

$25.74

$48.60

Volume

133,438 shs

Average Volume

491,386 shs

Market Capitalization

$1.25 billion

P/E Ratio

33.21

Dividend Yield

N/A

Beta

0.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Pacira BioSciences?: The following Wall Street sell-side analysts have issued research reports on Pacira BioSciences in the last twelve months: Barclays PLC, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, Raymond James, Royal Bank of Canada, StockNews.com, TD Cowen, TheStreet, Truist Financial Co., and Wedbush.
View the latest analyst ratings for PCRX.
What is the current price target for Pacira BioSciences?: 10 Wall Street analysts have set twelve-month price targets for Pacira BioSciences in the last year. Their average twelve-month price target is $49.50, suggesting a possible upside of 89.7%. Barclays PLC has the highest price target set, predicting PCRX will reach $57.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $42.00 for Pacira BioSciences in the next year.
View the latest price targets for PCRX.
What is the current consensus analyst rating for Pacira BioSciences?: Pacira BioSciences currently has 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PCRX will outperform the market and that investors should add to their positions of Pacira BioSciences.
View the latest ratings for PCRX.
What other companies compete with Pacira BioSciences?: Other companies that are similar to Pacira BioSciences include Supernus Pharmaceuticals, OPKO Health, ALX Oncology, ADC Therapeutics and Atea Pharmaceuticals. Learn More about companies similar to Pacira BioSciences.
How do I contact Pacira BioSciences' investor relations team?: Pacira BioSciences' physical mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company's listed phone number is (813) 553-6680 and its investor relations email address is [email protected]. The official website for Pacira BioSciences is www.pacira.com. Learn More about contacing Pacira BioSciences investor relations.

Pacira BioSciences - PCRX Stock Price Target and Predictions

Analyst Price Target for PCRX

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.62 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Pacira BioSciences?

What is the current price target for Pacira BioSciences?

What is the current consensus analyst rating for Pacira BioSciences?

What other companies compete with Pacira BioSciences?

How do I contact Pacira BioSciences' investor relations team?